EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience

Roberto Cairoli iD, Lorenzo Del Castello, Silvia Imbergamo, Elisabetta Pierdomenico, Cristina Papayannidis iD, Erika Borlenghi iD, Calogero Vetro, Patrizia Chiusolo iD, Monica Fumagalli, Clara Minotti, Francesco Marchesi iD, Massimo Bernardi und 21 weitere

Cancer · 01.09.2025 · 131 (17)

DOI: 10.1002/cncr.70055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 21.08.2025. Verfasst von Roberto Cairoli und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Pyrazines, Aniline Compounds. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondazione Malattie del Sangue ETS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Methods This real‐world study evaluated the clinical effectiveness of gilteritinib in 205 patients with relapsed or refractory (R/R) FLT3‐mutated acute myeloid leukemia (AML) enrolled in the Italian expanded access since January 2018.

Results

Of the 205 patients, 124 (60.5%) received gilteritinib as a bridging therapy to allogeneic stem cell transplantation (allo‐SCT), achieving complete remission in 52.4% ( n = 65). The median overall survival (OS) for the entire cohort was 11.0 months, with estimated OS rates of 46.8% at 1 year and 28.5% at 3 years. Sixty patients (48% of those bridged) underwent allo‐SCT after a median of 3.7 months on gilteritinib, achieving posttransplant OS rates of 65.2% at 1 year and 56.1% at 3 years. The acquisition of FLT3 mutations at relapse and the presence of TP53 co‐mutations were significantly associated with inferior outcomes. Among 46 patients (22.4%) who relapsed after allo‐SCT, gilteritinib treatment yielded an overall response rate (ORR) of 54.3%, a median OS of 11.1 months, and 1‐ and 3‐year OS rates of 49.5% and 15.5%, respectively. Additionally, 35 patients (17.1%) previously treated with nonintensive chemotherapy received gilteritinib until disease progression or intolerance, achieving an ORR of 11.4%, a median OS of 5.9 months, and a 1‐year OS rate of 29.0%.

Conclusions

These real‐world data confirm that clinical outcomes achieved with gilteritinib in patients with R/R FLT3‐mutated AML are consistent with those observed in pivotal clinical trials. Notably, approximately half of the transplant‐eligible patients were successfully bridged to allo‐SCT and demonstrated encouraging long‐term survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcutePyrazinesAniline CompoundsProtein Kinase InhibitorsHumansFemaleMiddle AgedMaleAdultMutationAgedItalyYoung AdultAdolescentTreatment OutcomeHematopoietic Stem Cell Transplantation

Stichwörter der Autor:innen

FLT3acute myeloid leukemiagilteritinibreal‐worldtyrosine kinase inhibitor

Substanzen

fms-Like Tyrosine Kinase 3gilteritinibFLT3 protein, humanPyrazinesAniline CompoundsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
  • Department of Medicine and Surgery, University of Milano Bicocca, Milano, Italy.
  • Department of Clinical Research and Innovation, Bicocca Bioinformatics Biostatistics and Bioimaging Center B4, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy, ASST Grande Ospedale Metropolita…
  • Department of Medicine, Hematology and Clinical Immunology Unit, University of Padova, Padova, Italy.
  • Hematology Unit, Istituto Oncologico Veneto IRCCS, Castelfranco Veneto, Province of Treviso, Italy.
  • Istituto di Ematologia "Seragnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

ORCID-Profile: Roberto Cairoli, Cristina Papayannidis, Erika Borlenghi, Patrizia Chiusolo, Francesco Marchesi

Förderung

  • Fondazione Malattie del Sangue ETS

Zitieren

APA

Cairoli, R., Del Castello, L., Imbergamo, S., Pierdomenico, E., Papayannidis, C., Borlenghi, E., Vetro, C., Chiusolo, P., Fumagalli, M., Minotti, C., Marchesi, F., Bernardi, M., Musto, P., Fracchiolla, N., Candoni, A., Lunghi, M., Musso, M., Guolo, F., Mannina, D., …, & Greco, R. (2025). Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience. Cancer, 131(17). https://doi.org/10.1002/cncr.70055

Vancouver

Cairoli R, Del Castello L, Imbergamo S, Pierdomenico E, Papayannidis C, Borlenghi E, et al. Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience. Cancer. 2025;131(17). doi:10.1002/cncr.70055

BibTeX
@article{Cairoli2025,
  author = {Cairoli, Roberto and Del Castello, Lorenzo and Imbergamo, Silvia and Pierdomenico, Elisabetta and Papayannidis, Cristina and Borlenghi, Erika and Vetro, Calogero and Chiusolo, Patrizia and Fumagalli, Monica and Minotti, Clara and Marchesi, Francesco and Bernardi, Massimo and Musto, Pellegrino and Fracchiolla, Nicola and Candoni, Anna and Lunghi, Monia and Musso, Maurizio and Guolo, Fabio and Mannina, Donato and Lico, Albana and Scattolin, Anna Maria and Crugnola, Monica and Galimberti, Sara and Nadali, Gianpaolo and Turrini, Mauro and Zappasodi, Patrizia and Todisco, Elisabetta and Basilico, Claudia and Grillo, Giovanni and Mancini, Valentina and Riva, Marta and Bernasconi, Davide Paolo and Greco, Rosa},
  title = {Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {17},
  doi = {10.1002/cncr.70055}
}
Kostenlos starten →